Business Context and Reporting Period
This Form 8-K, dated February 21, 2003, reports the completion of a merger between Manhattan Pharmaceuticals, Inc. (formerly Atlantic Technology Ventures, Inc.) and Manhattan Research Development Corp. (formerly Manhattan Pharmaceuticals, Inc.). The transaction was structured as a reverse acquisition, with Manhattan Research shareholders receiving approximately 80% of the post-merger equity. The filing includes historical financial statements for Manhattan Research for the period from its inception (August 6, 2001) through September 30, 2002, and unaudited pro forma combined financial information.
Key Financial Metrics
Manhattan Research (Historical - Nine Months Ended Sept 30, 2002):
- Revenue: $0 (Development stage company with no commercial sales).
- Net Loss: $(835,569).
- Operating Expenses: $823,456 (primarily R&D of $377,654 and consulting fees of $217,885).
- Cash Flow: Net cash used in operating activities was $(626,721); net cash provided by financing activities was $630,000.
- Liquidity: Cash and cash equivalents totaled $3,279 as of September 30, 2002.
- Debt: Total current liabilities were $888,203, including a $601,346 note payable and $161,846 in accounts payable.
- Stockholders' Deficiency: $(830,776).
Pro Forma Combined Entity (As of Sept 30, 2002):
- Total Assets: $3,329,474 (driven by $2,979,413 in recorded intangible assets).
- Net Loss (Nine Months): $(2,735,279).
- Pro Forma Cash: $179,124 (after adjusting for estimated merger expenses).
Material Changes and Transaction Details
The primary material change is the acquisition of Manhattan Research, which holds an exclusive worldwide license to intellectual property for oleoyl-estrone (OE), a drug candidate for weight loss. Key transaction details include:
- Exchange Ratio: Each share of Manhattan Research was converted into the right to receive approximately 13 shares of Manhattan common stock.
- Share Issuance: 83,620,271 shares of Manhattan common stock were issued to former Manhattan Research holders.
- Warrant Conversion: Warrants to purchase 864,280 shares of Manhattan Research were converted into warrants to purchase 9,839,313 shares of Manhattan common stock.
- Accounting Treatment: The merger is accounted for as a reverse acquisition. The preliminary purchase price is estimated at $2,979,413, allocated primarily to intangible assets (patents and licenses).
Outlook, Risks, and Management Commentary
Going Concern Uncertainty: The financial statements include a "Going Concern" note stating that the company has a significant working capital deficiency and accumulated deficit. The ability to continue operations is dependent on obtaining additional financing and achieving profitable operations.
Financing Activities:
- The company received a $600,000 note from an independent financial institution (due January 2003) and $30,000 from a stockholder.
- A private placement offering was commenced but had not closed as of September 30, 2002.
- Subsequent Events: In October 2002, the company received an additional $80,000 from a stockholder and collected $4,000 in subscription receivables.
Risks:
- Regulatory and Development Risk: The company is in the development stage; the drug candidate (OE) has only undergone pre-clinical animal studies.
- Liquidity Risk: Minimal cash on hand ($3,279) relative to liabilities ($888,203) creates immediate liquidity pressure.
- Valuation Risk: The pro forma financial information relies on preliminary valuations of intangible assets which may change upon final valuation.
Investor Verification Checklist
- Verify the status of the $600,000 note payable due in January 2003 and whether it has been repaid or refinanced.
- Confirm the final valuation of the intangible assets (patents and licenses) and the resulting amortization schedule.
- Assess the progress of the private placement offering and the company's ability to raise further capital to cover the working capital deficiency.
- Review the pre-clinical data for oleoyl-estrone (OE) to evaluate the commercial viability of the core asset.
- Check for any subsequent filings regarding the final closing of the merger and the exact share count post-transaction.